MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyad039

Медицинская библиотека · The oncologist · 2023

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.

Nardo Mirella, Yilmaz Bulent, Nelson Blessie Elizabeth, Torres Harrys A, Wang Lan Sun, Granwehr Bruno Palma, Song Juhee, Dalla Pria Hanna R F, Trinh Van A, Glitza Oliva Isabella C, Patel Sapna P, Tannir Nizar M, Kaseb Ahmed Omar, Altan Mehmet, Lee Sunyoung S, Miller Ethan, Zhang Hao, Stephen Bettzy A, Naing Aung

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

Despite the clinical benefit of immune checkpoint inhibitors (ICIs), patients with a viral hepatitis have been excluded from clinical trials because of safety concerns. The purpose of this study was to determine the incidence rate of adverse events (AEs) in patients with viral hepatitis who received ICIs for cancer treatment.

MATERIALS AND

METHODS

We conducted a retrospective study in patients with cancer and concurrent hepatitis B or C, who had undergone treatment with ICI at MD Anderson Cancer Center from January 1, 2010 to December 31, 2019.

RESULTS

Of the 1076 patients screened, we identified 33 with concurrent hepatitis. All 10 patients with HBV underwent concomitant antiviral therapy during ICI treatment. Sixteen of the 23 patients with HCV received it before the initiation of ICI. The median follow-up time was 33 months (95% CI, 23-45) and the median duration of ICI therapy was 3 months (IQR, 1.9-6.6). Of the 33 patients, 12 (39%) experienced irAEs (immune-related adverse events) of any grade, with 2 (6%) having grade 3 or higher. None of the patients developed hepatitis toxicities.

CONCLUSION

ICIs may be a therapeutic option with an acceptable safety profile in patients with cancer and advanced liver disease.

Для цитирования: Nardo Mirella, Yilmaz Bulent, Nelson Blessie Elizabeth, Torres Harrys A, Wang Lan Sun, Granwehr Bruno Palma, Song Juhee, Dalla Pria Hanna R F, Trinh Van A, Glitza Oliva Isabella C, Patel Sapna P, Tannir Nizar M, Kaseb Ahmed Omar, Altan Mehmet, Lee Sunyoung S, Miller Ethan, Zhang Hao, Stephen Bettzy A, Naing Aung. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience.. The oncologist. 2023. DOI: 10.1093/oncolo/oyad039.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.